High-pressure application breakthrough aids RWMC’s immunotherapy ambitions

IMMUNOTHERAPY TREATMENT: Roger Williams Medical Center physicians Dr. Steven Katz, left, and Dr. N. Joseph Espat are developing a high-pressure application of their immunotherapy treatment for cancer cells. It has been demonstrated to be an effective way to administer the drugs to tumors that are usually resistant to treatment.
 / PBN PHOTO/
DAVE HANSEN
IMMUNOTHERAPY TREATMENT: Roger Williams Medical Center physicians Dr. Steven Katz, left, and Dr. N. Joseph Espat are developing a high-pressure application of their immunotherapy treatment for cancer cells. It has been demonstrated to be an effective way to administer the drugs to tumors that are usually resistant to treatment.
 / PBN PHOTO/
DAVE HANSEN
T-cells genetically altered to seek and kill cancer don’t do much good if the tumor’s density stops it from contacting the offending tissue, a challenge Roger Williams Medical Center researchers have evidence they’ve overcome in a recent clinical trial of TriSalus Life Sciences’ pressure-enabled, drug-delivery ­catheter. Dr. Steven Katz, director of the Office of Therapeutic…

Subscriber-only Content

This article is available only to PBN Subscribers. To get unlimited access, please subscribe by following the link below.

Subscribe Now

Already a subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -